Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Monday 20 April 2020 9:48 am  |  Updated:  Monday 20 April 2020 9:56 am

UK to trial using Covid-19 survivors’ blood plasma for treatment

By: Reuters

Add as a preferred source on Google
The United Kingdom is preparing to collect the blood from coronavirus survivors to see if it can help create a treatment for the infection.
The United Kingdom is preparing to collect the blood from coronavirus survivors to see if it can help create a treatment for the infection.

The United Kingdom is preparing to collect the blood from Covid-19 survivors to see if it can help create a treatment for the infection.

British doctors will investigate if convalescent plasma transfusions could improve an infected patient’s speed of recovery and chances of survival.

“NHS Blood and Transplant is preparing to collect Covid-19 convalescent plasma from people who have recovered from this illness,” a spokeswoman said. “We envisage that this will be initially used in trials as a possible treatment for Covid-19.”

“If fully approved, the trials will investigate whether convalescent plasma transfusions could improve a Covid-19 patient’s speed of recovery and chances of survival,” the blood service said.

“We are working closely with the government and all relevant bodies to move through the approvals process as quickly as possible.”

People who have recovered from Covid-19 can register with the NHS if they are interested in donating plasma but they should not just turn up at blood donation centres.

Last week drugmaker Gilead confirmed a report in which its drug remdesivir led to a quick recovery in Covid-19 patients.

The University of Chicago Medicine’s trial recruited 113 people with severe Covid-19 to see how effective remdesivir was as a treatment. Two have died, but many others saw a rapid recovery that led to them being discharged.

Read more

Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Citroën 2CV returns as a £13,000 electric car, and the timing is no accident

  • Rachel Reeves to unveil next steps for ring-fencing reform at Mansion House

  • Wimbledon: HMRC set to slap Sinner and Noskova with £1.6m tax bill

  • Barclays and Lloyds back calls to digitalise UK markets and unlock £33bn boost

  • The former African gold miner taking on the billionaire Issa brothers

More from City PM

  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • The Bath House banya: Contrast therapy in Belgravia

    Life&Style
    Historic bath house exterior with ornate architecture, showcasing vintage design elements and a serene garden setting.
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Are office workers lonelier than they were during Covid WFH?

    Business
    A third of Brits feel lonely at work, with almost a fifth regularly going a full day without speaking to anyone.
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook